Form 4: Xeris Biopharma Holdings Director John P. Schmid Increases Stake in Company

Director John P. Schmid reports purchasing 5,400 shares of Xeris Biopharma Holdings at $1.91 per share on May 10, 2024, increasing his total holdings.

Summary

• On May 10, 2024, John P. Schmid, a director of Xeris Biopharma Holdings, Inc., purchased 5,400 shares of common stock at a price of $1.91 per share.
• This transaction increased Schmid's direct holdings to 63,159 shares.
• Schmid also indirectly owns 16,400 shares through The Schmid Family Trust dated August 15, 2017.
• He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. A director buying shares is generally viewed as a positive sign, but without additional context, it's difficult to assess the overall impact.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The stock purchase by a director could positively influence shareholder sentiment.

Key Dates